3-amino-3-(meta-nitrophenyl)-acrylic acid methyl ester | 113293-77-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-amino-3-(meta-nitrophenyl)-acrylic acid methyl ester
• 英文别名: Methyl 3-amino-3-(3-nitrophenyl)prop-2-enoate
• CAS: 113293-77-9
• 化学式: C₁₀H₁₀N₂O₄
• 分子量: 222.2
• InChiKey: BVIKJDUKITYPIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  98.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-amino-3-(meta-nitrophenyl)-acrylic acid methyl ester 、 1-苯基-2-丁烯-1-酮 在 苯 作用下， 以 正丁醇 为溶剂， 反应 4.0h， 以to give methyl 4-methyl-2-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxylate (4.10 g)的产率得到methyl 4-methyl-2-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxylate
  参考文献：
  名称：

  N-containing heterocyclic compounds, and composition comprising the same

  摘要：

  本发明涉及一种药物组合物，作为缺血性疾病的治疗剂，包括式中的化合物：##STR1##其中，R.sup.1是以吗啡环(lower)烷基、硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基；或以(lower)烷基氨(lower)烷基取代的脲基；R.sup.2是以硝基取代的苯基，R.sup.4是(lower)烷基；或R.sup.2是(lower)烷基，R.sup.4是以硝基取代的苯基；但前提是当R.sup.4是(lower)烷基时，R.sup.1是以硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基或以(lower)烷基氨(lower)烷基取代的脲基；或其盐，作为活性成分，与药学上可接受的、基本无毒的载体或赋形剂相结合。

  公开号：

  US04990507A1
• 作为产物：
  描述：

  dimethyl propanedioate 、 氢氧化钾 在 甲醇 作用下， 以 甲醇 、 水 为溶剂， 反应 8.0h， 以to give methyl 3-amino-3-(3-nitrophenyl)acrylate (50.2 g)的产率得到3-amino-3-(meta-nitrophenyl)-acrylic acid methyl ester
  参考文献：
  名称：

  N-containing heterocyclic compounds, and composition comprising the same

  摘要：

  本发明涉及一种药物组合物，作为缺血性疾病的治疗剂，包括式中的化合物：##STR1##其中，R.sup.1是以吗啡环(lower)烷基、硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基；或以(lower)烷基氨(lower)烷基取代的脲基；R.sup.2是以硝基取代的苯基，R.sup.4是(lower)烷基；或R.sup.2是(lower)烷基，R.sup.4是以硝基取代的苯基；但前提是当R.sup.4是(lower)烷基时，R.sup.1是以硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基或以(lower)烷基氨(lower)烷基取代的脲基；或其盐，作为活性成分，与药学上可接受的、基本无毒的载体或赋形剂相结合。

  公开号：

  US04990507A1

文献信息

• [EN] E-ISOMERIC beta-AROMATIC OR HETEROAROMATIC SUBSTITUTED beta-ACYLAMINO-ACRYLATES AND METHODS OF PREPARING THE SAME<br/>[FR] DOLLAR G(B)-ACYLAMINO-ACRYLATES E-ISOMERES A SUBSTITUTION DOLLAR G(B)-AROMATIQUE OU HETEROAROMATIQUE ET LEUR PROCEDES DE PREPARATION
  申请人：DSM IP ASSETS BV

  公开号：WO2004011414A1

  公开（公告）日：2004-02-05

  E-isomeric ß-(hetero) aromatically substituted acylaminoacrylates are of great economic interest since with them, by means of hydration, precursors of appropriately substituted (ß-amino acids can be prepared and, by doing so, lead to higher enantio-selectivities than the corresponding Z-isomers. The invention describes novel E-isomeric R-aromatically or ß-heteroaromatically substituted ß-acylaminoacrylates of the general formula (I): in which R represents hydrogen or a substituted or unsubstituted alkyl or aromatic or heteroaromatic residue, and R' represents a substituted or unsubstituted aromatic or heteroaromatic residue, R' represents H, a substituted or unsubstituted alkyl or aromatic or heteroaromatic residue, and R'' represents H, a substituted or unsubstituted alkyl, acyl, aromatic or heteroaromatic residue. According to the invention, the compounds according to the general formula (I) are prepared by acylation at temperatures below the boiling point of the reaction mixture.

  E-异构体ß-(杂)芳基取代的酰胺基丙烯酸酯具有巨大的经济价值，因为通过水合作用，可以制备适当取代的(ß-氨基酸的前体，并且通过这种方式，可以实现比相应的Z-异构体更高的对映选择性。该发明描述了一种新颖的E-异构体R-芳基或ß-杂芳基取代的ß-酰胺基丙烯酸酯，其一般式为(I)：其中R代表氢或取代或未取代的烷基或芳基或杂芳基残基，R'代表取代或未取代的芳基或杂芳基残基，R''代表氢，取代或未取代的烷基或芳基或杂芳基残基。根据该发明，按照一般式(I)的化合物是通过在低于反应混合物沸点的温度下进行酰化制备的。
• Di phenylpyridazine compounds, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04931453A1

  公开（公告）日：1990-06-05

  The invention relates to diphenylpyridazine compounds useful in the treatment of cerebrovascular disease, of the formula: ##STR1## wherein R.sup.1 is piperazinyl(lower)alkyl, carbamoyl substituted with piperazinyl(lower)alkyl, or piperazinylcarbonyl, in each of which a piperazinyl group may be substituted with lower alkyl, R.sup.2 is phenyl substituted with nitro, and R.sup.3 is hydrogen or halogen, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种用于治疗脑血管疾病的二苯吡嗪化合物，其化学式为：##STR1## 其中R.sup.1是哌嗪基（较低）烷基，用哌嗪基（较低）烷基取代的氨基甲酰基，或哌嗪基甲酰基，其中哌嗪基可以被较低烷基取代；R.sup.2是取代有硝基的苯基；R.sup.3是氢或卤素，或其药学上可接受的盐。
• Diphenylpyridine compounds, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04831030A1

  公开（公告）日：1989-05-16

  The invention relates to compounds for treatment of hypertension, and cardiovascular and cerebrovascular diseases, which compounds are of the formula: ##STR1## wherein R.sup.1 is piperazinyl(lower)alkyl, carbamoyl substituted with piperazinyl(lower)alkyl, or piperazinylcarbonyl, in each of which a piperazinyl group may be substituted with lower alkyl, and R.sup.3 is hydrogen or halogen; R.sup.2 is phenyl substituted with nitro, and R.sup.4 is lower alkyl or halo(lower)alkyl; or R.sup.2 is lower alkyl, and R.sup.4 is phenyl substitured with nitro; and a pharmaceutically acceptable salt thereof.

  本发明涉及用于治疗高血压、心血管和脑血管疾病的化合物，该化合物的化学式为：##STR1##其中R.sup.1是哌嗪基(较低)烷基、用哌嗪基(较低)烷基取代的氨基甲酰基或哌嗪基甲酰基，其中哌嗪基团可以用较低烷基取代，R.sup.3是氢或卤素；R.sup.2是取代有硝基的苯基，R.sup.4是较低烷基或卤代(较低)烷基；或者R.sup.2是较低烷基，R.sup.4是取代有硝基的苯基；以及其药学上可接受的盐。
• Morpholine containing pyridine compounds, compositions and use
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04857527A1

  公开（公告）日：1989-08-15

  An N-containing heterocyclic compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl optionally substituted with hydroxy, halogen or a heterocyclic group, carboxy, esterified carboxy, carbamoyl optionally substituted with heterocyclic(lower)alkyl or lower alkylamino(lower)alkyl, N-containing heterocycliccarbonyl optionally substituted with lower alkyl, or ureido optionally substituted with lower alkylamino(lower)alkyl, and R.sup.3 is hydrogen or halogen; R.sup.2 is phenyl substituted with nitro, and X is .dbd.N--or ##STR2## in which R.sup.4 is lower alkyl or halo(lower)alkyl, or is taken together with R.sup.1 to form an N-containing heterocyclic group optionally substituted with oxo and lower alkylamino(lower)alkyl; or R.sup.2 is lower alkyl, and X is ##STR3## in which R.sup.4 is phenyl substituted with nitro; and a pharmaceutically acceptable salt thereof, processes for the preparation thereof and pharmaceutical (e.g. antihypertension) compositions comprising the same.

  一种含氮杂环化合物，化学式为：##STR1## 其中R.sup.1是低碳基，可选用羟基，卤素或杂环基取代，羧基，酯化羧基，氨基甲酰基，可选用杂环（低）烷基或低碳基氨基（低）烷基取代的含氮杂环羰基或取代低碳基的尿素基或低碳基氨基（低）烷基取代的尿素基，R.sup.3为氢或卤素；R.sup.2为取代硝基的苯基，X为.dbd.N--或##STR2##其中R.sup.4为低碳基或卤代（低）烷基，或与R.sup.1共同形成含氮杂环基，可选用氧代和低碳基氨基（低）烷基取代；或R.sup.2为低碳基，X为##STR3##其中R.sup.4为取代硝基的苯基；以及其药学上可接受的盐，其制备方法和包含其的药物（例如降压）组成物。
• N-containing heterocyclic compounds, and composition comprising the same
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04990507A1

  公开（公告）日：1991-02-05

  The invention relates to a pharmaceutical composition as a therapeutic agent for ischemic disease comprising a compound of the formula ##STR1## wherein R.sup.1 is carbamoyl substituted with morpholino (lower) alkyl, thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl; and R.sup.2 is phenyl substituted with nitro, and R.sup.4 is lower alkyl; or R.sup.2 is lower alkyl, and R.sup.4 is phenyl substituted with nitro; with proviso that R.sup.1 is carbamoyl substituted with thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl when R.sup.4 is lower alkyl; or its salt, as an active ingredient, in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.

  本发明涉及一种药物组合物，作为缺血性疾病的治疗剂，包括式中的化合物：##STR1##其中，R.sup.1是以吗啡环(lower)烷基、硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基；或以(lower)烷基氨(lower)烷基取代的脲基；R.sup.2是以硝基取代的苯基，R.sup.4是(lower)烷基；或R.sup.2是(lower)烷基，R.sup.4是以硝基取代的苯基；但前提是当R.sup.4是(lower)烷基时，R.sup.1是以硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基或以(lower)烷基氨(lower)烷基取代的脲基；或其盐，作为活性成分，与药学上可接受的、基本无毒的载体或赋形剂相结合。